生物信息学
公共化学
蛋白酶
冠状病毒
计算生物学
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
效力
体外
蛋白酶抑制剂(药理学)
细胞培养
病毒学
2019年冠状病毒病(COVID-19)
化学
生物
药理学
病毒
医学
生物化学
酶
病毒载量
传染病(医学专业)
遗传学
基因
病理
抗逆转录病毒疗法
疾病
作者
Aditya Trivedi,Vandana Kardam,Krishna Kishore Inampudi,Sudhanshu Vrati,Dharmender Gupta,Aekagra Singh,Sarala Rani Kayampeta,Mohan Babu Appaiahgari,Deepak Sehgal
出处
期刊:FEBS Journal
[Wiley]
日期:2023-09-01
卷期号:290 (23): 5496-5513
被引量:6
摘要
The recurrent nature of coronavirus outbreaks, severity of the COVID‐19 pandemic, rapid emergence of novel variants, and concerns over the effectiveness of existing vaccines against novel variants have highlighted the need to develop therapeutic interventions. Targeted efforts to identify inhibitors of crucial viral proteins are the preferred strategy. In this study, we screened FDA‐approved and natural product libraries using in silico approach for potential hits against the SARS‐CoV‐2 main protease (Mpro) and experimentally validated their potency using in vitro biochemical and cell‐based assays. Seven potential hits were identified through in silico screening and were subsequently evaluated in SARS‐CoV‐2‐based cell‐free assays, followed by testing in the HCoV‐229E‐based culture system. Of the tested compounds, 4‐(3,4‐dihydroxyphenyl)‐6,7‐dihydroxy‐1‐isopropyl‐1H‐benzofuro[3,2‐b]pyrazolo[4,3‐e]pyridin‐3(2H)‐one (PubChem CID:71755304, hereafter referred to as STL522228) exhibited significant antiviral activity. Subsequently, its potential as a novel COVID therapeutic molecule was validated in the SARS‐CoV‐2‐culture system, where STL522228 demonstrated superior antiviral activity (EC 50 = 0.44 μ m ) compared to Remdesivir (EC 50 = 0.62 μ m ). Based on these findings, we report the strong anti‐coronavirus activity of STL522228, and propose that it as a promising pan‐ coronavirus Mpro inhibitor for further experimental and preclinical validation.
科研通智能强力驱动
Strongly Powered by AbleSci AI